Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group.

@article{Knaus1996UseOP,
  title={Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group.},
  author={William A. Knaus and Frank E. Harrell and J Labrecque and Douglas P. Wagner and John P. Pribble and Elizabeth A. Draper and Charles J Fisher and L Soll},
  journal={Critical care medicine},
  year={1996},
  volume={24 1},
  pages={46-56}
}
OBJECTIVES To investigate a novel anticytokine therapy in patients with sepsis syndrome, and the relationship between a patient's baseline mortality risk and survival benefit. DESIGN Data from a recent phase III, double-blind, placebo-controlled, multicenter clinical trial with patients randomized to three treatment arms: an intravenous loading dose of recombinant human interleukin-1-receptor antagonist (rhIL-1ra) or placebo, followed by a continuous infusion of rhIL-1ra (1.0 mg/kg/hr, or 2.0… CONTINUE READING